Literature DB >> 34529139

It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development.

Catriona Parker1,2, Andrew Wei3,4, Danny Liew3,5, Ella Zomer3, Darshini Ayton6.   

Abstract

Patient reported outcomes (PROs) are a pillar of modern-day patient-centered care and clinical trials. PROs complement clinical information with the patient's own report about their experiences of health, without influence or interpretation by other people. However, choosing an appropriate PRO measure from the many available remains challenging for clinicians and researchers. One of the common pitfalls in instrument selection is that the instrument is often developed with a different patient population than the group being cared for or researched. This difference can result in salient items of importance to the patients, being under-reported or missed altogether. We highlight, through the reporting of some of our own data, that PRO instrument development does not stop with a validation study and we provide suggestions for future research for further improvement in this space.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Acute leukaemia; Acute myeloid leukaemia; Cancer; Patient reported outcome measures

Mesh:

Year:  2021        PMID: 34529139     DOI: 10.1007/s00520-021-06553-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  13 in total

Review 1.  Comparative responsiveness of generic and specific quality-of-life instruments.

Authors:  Samuel Wiebe; Gordon Guyatt; Bruce Weaver; Suzan Matijevic; Casey Sidwell
Journal:  J Clin Epidemiol       Date:  2003-01       Impact factor: 6.437

2.  The routine use of patient reported outcome measures in healthcare settings.

Authors:  Jill Dawson; Helen Doll; Ray Fitzpatrick; Crispin Jenkinson; Andrew J Carr
Journal:  BMJ       Date:  2010-01-18

3.  Underreporting by cancer patients: the case of response-shift.

Authors:  I S Breetvelt; F S Van Dam
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

Review 4.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods.

Authors:  Lori D McLeod; Cheryl D Coon; Susan A Martin; Sheri E Fehnel; Ron D Hays
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

5.  Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire.

Authors:  David Cella; Sally E Jensen; Kimberly Webster; Du Hongyan; Jin-Shei Lai; Steven Rosen; Martin S Tallman; Susan Yount
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

6.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 7.  Patient-reported outcomes in acute myeloid leukemia: Where are we now?

Authors:  Sarah A Buckley; Kedar Kirtane; Roland B Walter; Stephanie J Lee; Gary H Lyman
Journal:  Blood Rev       Date:  2017-09-01       Impact factor: 8.250

8.  Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs).

Authors:  Theresa Weldring; Sheree M S Smith
Journal:  Health Serv Insights       Date:  2013-08-04

Review 9.  Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.

Authors:  Ellen E Korol; Sisi Wang; Karissa Johnston; Farhad Ravandi-Kashani; Mark Levis; Floortje van Nooten
Journal:  Oncol Ther       Date:  2017-01-27

10.  The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.

Authors:  Samantha Cruz Rivera; Derek G Kyte; Olalekan Lee Aiyegbusi; Anita L Slade; Christel McMullan; Melanie J Calvert
Journal:  Health Qual Life Outcomes       Date:  2019-10-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.